Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RG7667
- Development stage
- Phase 2
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**RG7667** is an investigational intravenous anti-cytomegalovirus combination therapy developed by Genentech. It contains two anti-CMV immunoglobulin G1 monoclonal antibodies, MCMV5322A and MCMV3068A, designed to neutralize human cytomegalovirus by binding viral envelope glycoprotein complexes and blocking viral entry into susceptible host cells. It was evaluated through Phase 2 for prevention of cytomegalovirus infection and disease in high-risk kidney-transplant recipients. ([journals.asm.org](https://journals.asm.org/doi/10.1128/aac.01108-17))
- Other names
- MCMV5322A + MCMV3068A
02
Targets
GH (Growth hormone)HCMV Pentamer (HCMV pentameric glycoprotein complex)
Beyond the preview
Go deeper on RG7667.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RG7667.